ClinicalTrials.gg
RecruitingNCT05991388Glo-BNHLUpdated Feb 20, 2026

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

A Phase 2/3 interventional study of Odronextamab and Loncastuximab tesirine in B-cell Non Hodgkin Lymphoma, sponsored by University of Birmingham. Recruiting at 11 sites in 7 countries. Open to participants aged Up to 25 Years. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by University of Birmingham · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
210
Allocation
Non-randomized
Ages
Up to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Lymphoma, B-Cell with a site in Australia — 18 open to participants now, 38 under way, 14 of them phase 3. Lymphoma, B-Cell · Australia.

Planned enrollment
31st of 63
210 · median 188
Started
2024
with 9 others
Phase 2/3
2 of 63
1 open now
Primary completion
2031-05
later than 36 of 37 live
Registered
45th of 63
by date

Among the 63 studies in Lymphoma, B-Cell with a site in Australia, this one is the 31st largest by planned enrollment, is one of 10 that started in 2024, is one of 2 in phase 2/3, reaches primary completion later than 36 of the 37 other live ones, and was the 45th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

18 of the 63 studies in Lymphoma, B-Cell with a site in Australia are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: Up to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Lymphoma, B-Cell with a site in Australia, or all of them as a file.
02

Study summary

The Glo-BNHL trial is trying to find better medicines for children and young people with B-cell non-Hodgkin Lymphoma (B-NHL) that does not go away (refractory B-NHL) or does but comes back again (relapsed B-NHL). B-NHL is a type of cancer that develops inside or outside of lymph nodes (glands) and organs such as the liver or spleen. Examples of B-NHL are Burkitt Lymphoma and Diffuse Large B Cell Lymphoma, which may be other names used to describe this type of cancer. It is very difficult to cure relapsed or refractory B-NHL. The medicines used now are very powerful with many side effects and only cure around 30 in every 100 children treated. It is very important that investigators quickly find better medicines for these children and young people.

The Glo-BNHL trial will include three groups of children and young people, each given a new medicine (either alone or with chemotherapy). The investigators are looking to make sure the new medicines are safe and that they work to treat the cancer. If the medicine in one group does not work for a child in the trial, then they may be able to join a different group to have another new medicine.

Experts from around the world will carefully pick the medicines most likely to be helpful to be part of the trial. If one of the new medicines seems not to be working as well as hoped then the investigators will take it out of the trial as soon as possible. This will let other new medicines be added to the trial and tested. If a medicine does seem to be working well, then it will continue in the trial to make sure it really is the most useful medicine available.

Children from around the world will be invited to take part in the trial. The investigators will then check on them for at least two years after they finish the trial treatment to look for possible side effects of the new medicine.

Read the detailed description

Glo-BNHL is an adaptive prospective international multicentre platform clinical trial designed to evaluate the safety and efficacy of novel agents for the treatment of children, adolescents, and young adults with relapsed and/or refractory B-cell non-Hodgkin Lymphoma (r/r BNHL). The trial is designed to generate sufficient evidence to potentially be practice-changing in this rare cancer setting. With the trial incorporating an initial stage evaluating efficacy followed potentially by an expansion stage to provide confirmatory analysis, the trial could be considered to be phase II/III.

Novel agents will be prioritised for inclusion in the platform according to an overarching prioritisation list and a robust systematic scientific assessment, performed by the international Trial Steering Committee (TSC).

The platform consists of three parallel treatment arms, each one investigating a different novel agent in a group of patients. The platform allows the testing of a pipeline of novel agents in each treatment arm consecutively. Patients in the platform may be enrolled into any of the available treatment arms for which they are eligible. The classes of novel agents prioritised for inclusion at the initiation of the trial are:

  • Treatment Arm I: Bispecific antibodies (BsAbs)
  • Treatment Arm II: Antibody-drug conjugates (ADC) with standard chemotherapy
  • Treatment Arm III: Chimeric antigen receptor (CAR) T-cells

The platform trial has an adaptive Bayesian design that facilitates efficient GO/NoGO decisions relevant to the target population enrolled in each treatment arm. The Bayesian approach estimates the probability that a novel agent is clinically effective and enables decision-making even with small numbers of patients. It can also incorporate prior knowledge, thereby maximising the utility of all available data in this rare population. It facilitates continuous evaluation of any novel agent as the sample size increases.

Furthermore it allows for the discontinuation of an agent if the observed trial data demonstrate a high probability that the novel agent is ineffective at any time, allowing the next agent in the pipeline to be introduced. If the prioritisation of classes of novel agents by the TSC changes, treatment arms can be amended, added, or removed to reflect this. Not all Treatment Arms will necessarily be open to recruitment at all times.

03

Conditions studied

  • B-cell Non Hodgkin Lymphoma

Browse trials for

04

Who can participate

Ages eligible
Up to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria applicable to all treatment arms:

  • proven mature B-NHL (Diffuse Large B-Cell Lymphoma (DLBCL), Burkitt Lymphoma/Leukaemia or atypical Burkitt/Burkitt-like lymphoma, primary mediastinal large B-cell lymphoma (PMLBL), and mature B-NHL/Not Otherwise Specified (NOS)) at initial diagnosis
  • Radiologically and/or histologically proven B-NHL in first relapse (only one ) or subsequent relapse (more than one prior line of therapy) or (*) B-NHL. (Note: relapses following prior targeted therapy must have continuing target positivity, confirmed by an established method).
  • If relapse occurs more than two years after previous therapy, a must be performed
  • Evaluable disease as per the international paediatric non-Hodgkin Lymphoma response criteria, including:

    • at least one bi-dimensionally measurable nodal lesion >1.5 cm in its longest dimension;
    • or at least one bi-dimensionally measurable extra-nodal lesion >1.0 cm in its longest dimension on computerised tomography (CT) or Magnetic Resonance Imaging (MRI);
    • or bone marrow involvement (≥25% involvement from bone marrow, if only site of disease. Any standard method of assessment is acceptable i.e. cytomorphology, flow cytometry and/or immunohistochemistry);
    • or, dependent on treatment arm, evaluable Central Nervous System (CNS) only disease (evaluable by imaging or Cerebrospinal Fluid (CSF) analysis)(**)
  • Age from birth to ≤25 years old at the time of trial entry
  • Performance status ≥50 using or Lansky performance scores
  • of ≥8 weeks
  • Adequate bone marrow function documented by:

    • count ≥50x 10\^9/L (no platelet transfusion therapy within seven days prior to treatment) unless bone marrow involvement(***)
    • (ANC) ≥0.75 x 10\^9/L (no granulocyte colony stimulating factor within 2 days prior to treatment) unless bone marrow involvement(***)
  • Adequate hepatic function documented by:

    • (AST) and/or alanine aminotransferase (ALT) ≤5 x (ULN)
    • Total ≤1.5 X ULN ***Patients with known Gilbert syndrome will be excluded if the total bilirubin value is >4 x ULN for the local general population
  • Documented negative pregnancy test for female patients of within seven days prior to trial entry
  • Patients of agrees to use effective whilst on trial treatment and for 12 months following treatment discontinuation
  • Written given by patient and/or parents/legal representative

Inclusion criteria applicable to treatment arm I only:

  • Male patients of reproductive potential must agree not to donate sperm whilst on trial treatment and for 6 months following treatment discontinuation
  • Adequate renal function, >45 ml/min by measurement or estimation (if creatinine levels are normal for the patient's age, using the Cockroft-Gault Equation is sufficient)
  • For patients with bone marrow involvement(***) or splenic sequestration, adequate bone marrow function documented by:

    • Platelet count ≥25 x 10\^9/L (no platelet transfusion therapy within three days prior to treatment)
    • level ≥7 g/dL
    • Absolute neutrophil count (ANC) ≥0.5 x 10\^9/L (no granulocyte colony stimulating factor within two days prior to treatment)
  • Patients who have received CAR T-cell therapy or other cellular therapies more than 28 days prior must demonstrate recovery from acute toxicities and have

Inclusion criteria applicable to treatment arm II only:

  • Adequate renal function, by measured (GFR) >60 ml/min/1.73m\^2 (estimated GFR is not sufficient)
  • For patients with bone marrow involvement(***) or splenic sequestration, requirements for bone marrow function do not apply

(*) Refractory disease

The following patients are considered to have refractory disease and can be included in this trial:

  • Patients with who do not achieve PR or CR with last therapy
  • Patients with partial response to last therapy (biopsy proven), with no evidence of progression

(**) CNS only disease Patients with CNS only disease may be eligible depending on the treatment arm. Please refer to the relevant treatment arm specific eligibility criteria.

(***) Bone marrow involvement Patients who have ≥ 25% blasts in the bone marrow are considered to have bone marrow involvement. For these patients, requirements for bone marrow function are dependent on treatment arm. Please refer to the relevant treatment arm specific eligibility criteria.

Exclusion Criteria:

  • B-cell Acute Lymphoblastic Leukaemia (B-ALL)/B-cell Lymphoblastic Lymphoma (B-LBL)
  • Patients within:

    • 90 days after an allogenic procedure
    • 45 days after an autologous HSCT procedure
    • 28 days of experiencing (GvHD) requiring systemic therapy, and/or treatment
    • 14 days of previous treatment
    • 28 days of receiving craniospinal radiation; or 14 days of any other radiation
    • For patients who have received any CAR T-cell therapy or other cellular therapies, see treatment arm specific eligibility criteria
  • Patients who have ongoing acute toxicities from most recent lymphoma directed therapy
  • Patients with known DNA repair disorder or known primary immunodeficiency
  • Patients who are pregnant or breastfeeding (exclusively or partially)
  • Patients who cannot regularly be followed up in accordance with the protocol due to psychological, social, geographical or other issues
  • Patients for whom non-compliance with treatment or trial procedures is expected
  • Uncontrolled concomitant infection. Severe infection (such as sepsis, pneumonia, etc.) should be clinically controlled at the time of trial entry
  • Known positivity
  • carrier status, history of Hepatitis B Virus or positive serology. A patient is considered as a Hepatitis B Virus carrier or to have (had) Hepatitis B Virus infection in case of:

    • Unimmunized and HBsAg and/or anti-HBs antibody and/or anti- HBc antibody positive,
    • Immunized and HBsAg and/or anti-HBc antibody positive.
  • within 28 days prior to trial entry
  • Known history of to any of the treatments or

Exclusion criteria applicable to treatment arm I only:

  • Central Nervous System (CNS) only disease
  • Patients within 28 days of any CAR-T cell therapy or other cellular therapies
  • Left ventricular shortening fraction (LVSF) \<27% or (LVEF) \<50%, as determined by ECHO or MUGA, any evidence of pericardial effusion (except trace or physiological) as determined by an ECHO, and any arrhythmias
  • Known CD20 negative disease at initial diagnosis
  • Seizure within the last 12 months
  • Prior treatment with CD20 x CD3 bispecific therapy
  • Known hypersensitivity to both allopurinol and rasburicase

Exclusion criteria applicable to treatment arm II only:

  • Patients within 42 days of any CAR-T cell therapy or other cellular therapies
  • Clinically significant (Grade ≥2) third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)
  • treatment for more than a total of seven days in the 14 days prior to trial entry
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Treatment Arm I - BsAb - Odronextamab

    Patients will receive odronextamab given as an intravenous infusion weekly for 12 weeks, then every two weeks until nine months, and every four weeks thereafter until progression or for a maximum of two years

    Drug: Odronextamab

  • Experimental
    Treatment Arm II - ADC with Standard Chemotherapy - Loncastuximab tesirine with modified R-ICE

    Patients will receive loncastuximab tesirine given as a 30-minute intravenous infusion with each cycle of modified R-ICE (maximum three cycles)

    Drug: Loncastuximab tesirine · Drug: Rituximab · Drug: Ifosfamide · Drug: Carboplatin · Drug: Etoposide · Drug: Etoposide Phosphate · Drug: Dexamethasone

  • Experimental
    Treatment Arm III - CAR T-cells - TBC

    Patients will receive CAR-T cell therapy - agent TBC

    Biological: CAR T-cells (TBC)

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment Arm I: BsAb: Occurrence of an objective response (OR)

    Occurrence of an objective response (OR) i.e. Complete Response (CR) or Partial Response (PR) after 12 weeks of treatment assessed by Independent Central Review (according to International Paediatric Non-Hodgkin Lymphoma Response Criteria)

    Time frame: At the end of week 12 of treatment

  2. Treatment Arm II: ADC with standard chemotherapy: Occurrence of CR

    Occurrence of CR within a maximum of three cycles of treatment assessed by Independent Central Review (according to International Paediatric Non-Hodgkin Lymphoma Response Criteria)

    Time frame: At the end of Cycle 2 and Cycle 3 of treatment (each cycle is 28 days)

Secondary outcomes

  1. Event-free survival time (EFS)

    All treatment arms

    Time frame: From start of treatment until last patient has been followed up for 2 years

  2. Progression-free survival time (PFS)

    All treatment arms

    Time frame: From start of treatment until last patient has been followed up for 2 years

  3. Overall survival time (OS)

    All treatment arms

    Time frame: From start of treatment until last patient has been followed up for 2 years

  4. Best overall response (BOR) during treatment

    All treatment arms

    Time frame: At the end of weeks 4, 8, and 12 for Treatment Arm I; at the end of cycles 1, 2, and 3 for Treatment Arm II (each cycle is 28 days)

  5. Duration of response (DOR)

    All treatment arms

    Time frame: From start of treatment until last patient has been followed up for 2 years

  6. Occurrence of an objective response (OR), where relevant

    Treatment arm specific

    Time frame: At the end of cycles 1, 2, and 3 (each cycle is 28 days)

  7. Occurrence of adverse events of special interest (AESI)

    Treatment arm specific

    Time frame: From start of treatment until 90 days after last day of treatment

  8. Occurrence of treatment emergent adverse events (TEAEs), where relevant

    Treatment arm specific

    Time frame: From start of treatment until 90 days after last dose

07

Study locations

6 of 11 sites recruiting
  • The Children's Hospital at Westmead
    Sydney, New South Wales, Australia
    Not yet recruiting
    • Caroline Bateman · Contact
    • Caroline Bateman · Principal investigator
  • Queensland Children's Hospital
    Brisbane, Queensland, Australia
    Not yet recruiting
    • Morag Whyte · Contact
    • Morag Whyte · Principal investigator
  • Perth Children's Hospital
    Perth, Washington, Australia
    Recruiting
    • Michelle Ng · Contact
    • Michelle Ng · Principal investigator
  • St. Anna Children's Hospital
    Vienna, Austria
    Recruiting
    • Andishe Attarbaschi · Contact
    • Andishe Attarbaschi · Principal investigator
  • UZ Leuven
    Leuven, Belgium
    Not yet recruiting
    • Anne Uyttebroeck · Contact
    • Anne Uyttebroeck · Principal investigator
  • Princess Máxima Centre for Pediatric Oncology
    Utrecht, Netherlands
    Recruiting
    • Erica Brivio · Contact
    • Erica Brivio · Principal investigator
  • Starship Children's Hospital
    Auckland, New Zealand
    Not yet recruiting
    • Tim Prestidge · Contact
    • Tim Prestidge · Principal investigator
  • Sahlgrenska University Hospital
    Gothenburg, Sweden
    Not yet recruiting
    • Karin Mellgren · Contact
    • Karin Mellgren · Principal investigator
  • Birmingham Children's Hospital
    Birmingham, United Kingdom
    Recruiting
    • Amos Burke · Contact
    • Amos Burke · Principal investigator
  • Bristol Royal Hospital for Children
    Bristol, United Kingdom
    Recruiting
    • Emma Seaford · Contact
    • Emma Seaford · Principal investigator
  • Royal Manchester Children's Hospital
    Manchester, United Kingdom
    Recruiting
    • Guy Makin · Contact
    • Guy Makin · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for May 2031, 83 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2023
First posted
Aug 14, 2023
StartActual
May 2, 2024
Primary completionEst.
May 1, 2031
CompletionEst.
May 1, 2033
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05991388
Collaborators
Cancer Research UK, Fight Kids Cancer, Regeneron Pharmaceuticals, ADC Therapeutics S.A.
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
May 2, 2024
Primary completion
May 1, 2031 (estimated)
Completion
May 1, 2033 (estimated)
Last update
Feb 20, 2026

Study contacts

Joseph Rogers
Contact
glo-BNHL@trials.bham.ac.uk
+44 (0)121 414 8040
Sarah Johnson
Contact
glo-BNHL@trials.bham.ac.uk
+44 (0)121 414 8040
Amos Burke
principal investigator · University of Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Odronextamab · Loncastuximab tesirine · Rituximab · Ifosfamide · Carboplatin · Etoposide · Etoposide phosphate · Dexamethasone · Chimeric Antigen Receptor T-cells

Start the discussion